A pilot study on the use of low dose erythropoietin in the management of human immunodeficiency virus (HIV) associated anaemia in Uganda

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN40084595

Enrollment

120

Registered

2007-08-06

Start date

2006-03-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV associated anaemia Haematological Disorders Other anaemias

Interventions

Each participant will be randomised to one of the following four groups: 1. Intervention group 1: Haematinics (one capsule orally once daily) and erythropoietin (Wepox) 2000 IU three times per week s

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Documented HIV positive 2. Grade 1 and 2 anaemia 3. Informed consent 4. Age 18 to 65 years

Exclusion criteria

Exclusion criteria: 1. Recent blood loss 2. Active opportunistic infection 3. Presence of fever at the time of enrolment 4. Pregnancy 5. Cancer chemotherapy 6. Severe microcytosis 7. Systemic hypertension 8. Known allergy to erythropoietin

Design outcomes

Primary

Measure	Time frame
Change in haemoglobin, measured at week 0 and end of week 4.	—

Secondary

Measure	Time frame
1. Quality of life improvement, measured at week 0 and end of week 4 using a visual analogue scale (LASA) and the Medical Outcomes Study HIV Health Survey (MOSHIV) instrument 2. Adverse events	—

Countries

Uganda

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026